Comparative Pharmacology
Head-to-head clinical analysis: BARHEMSYS versus BENDECTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARHEMSYS versus BENDECTIN.
BARHEMSYS vs BENDECTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BARHEMSYS (amisulpride) is a selective dopamine D2/D3 receptor antagonist. It also has weak affinity for serotonin 5-HT2A and 5-HT2B receptors, with no significant activity at other dopamine or serotonin receptor subtypes. Its antiemetic effect is primarily mediated through blockade of D2 receptors in the chemoreceptor trigger zone (CTZ).
Combination of doxylamine (antihistamine) and pyridoxine (vitamin B6). Doxylamine blocks histamine H1 receptors, reducing nausea and vomiting. Pyridoxine acts as a cofactor in neurotransmitter synthesis, modulating nausea pathways.
BARHEMSYS (amisulpride) 10 mg intravenously over 2 minutes, once daily for prevention of postoperative nausea and vomiting.
10 mg doxylamine succinate + 10 mg pyridoxine hydrochloride orally once daily at bedtime, increased to twice daily (one tablet in morning and one at bedtime) and then three times daily (one tablet in morning, one in midafternoon, and one at bedtime) as needed, max 4 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing in most patients.
Doxylamine: 10-12 hours (range 6-15h) in healthy adults; prolonged in hepatic impairment or elderly. Pyridoxine: 15-20 days (as pyridoxal phosphate in tissues); elimination half-life of pyridoxine per se is 2-3 hours.
Renal excretion accounts for approximately 50% of the dose as unchanged drug; fecal elimination (including biliary) accounts for approximately 30-40%.
Renal: mostly as metabolites. Doxylamine: ~60% as unchanged drug and metabolites; pyridoxine: ~70-80% as metabolites (primarily 4-pyridoxic acid). Fecal: minimal (<10%) for both components.
Category C
Category C
Antiemetic
Antiemetic